40 related articles for article (PubMed ID: 18289847)
1. Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase.
Kimball FS; Romero FA; Ezzili C; Garfunkle J; Rayl TJ; Hochstatter DG; Hwang I; Boger DL
J Med Chem; 2008 Feb; 51(4):937-47. PubMed ID: 18247553
[TBL] [Abstract][Full Text] [Related]
2. α-Ketoheterocycle inhibitors of fatty acid amide hydrolase: exploration of conformational constraints in the acyl side chain.
Duncan KK; Otrubova K; Boger DL
Bioorg Med Chem; 2014 May; 22(9):2763-70. PubMed ID: 24690529
[TBL] [Abstract][Full Text] [Related]
3. Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures.
Mileni M; Garfunkle J; DeMartino JK; Cravatt BF; Boger DL; Stevens RC
J Am Chem Soc; 2009 Aug; 131(30):10497-506. PubMed ID: 19722626
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of Structure-Activity Relationships of α-Ketoheterocycles as sn-1-Diacylglycerol Lipase α Inhibitors.
Janssen FJ; Baggelaar MP; Hummel JJ; Overkleeft HS; Cravatt BF; Boger DL; van der Stelt M
J Med Chem; 2015 Dec; 58(24):9742-53. PubMed ID: 26584396
[TBL] [Abstract][Full Text] [Related]
5. On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.
Paredes-Ruiz KJ; Chavira-Ramos K; Orozco-Morales M; Karasu C; Tinkov AA; Aschner M; Santamaría A; Colín-González AL
Neurotox Res; 2021 Dec; 39(6):2072-2097. PubMed ID: 34741755
[TBL] [Abstract][Full Text] [Related]
6. The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).
Otrubova K; Ezzili C; Boger DL
Bioorg Med Chem Lett; 2011 Aug; 21(16):4674-85. PubMed ID: 21764305
[TBL] [Abstract][Full Text] [Related]
7. Fluoride-mediated capture of a noncovalent bound state of a reversible covalent enzyme inhibitor: X-ray crystallographic analysis of an exceptionally potent α-ketoheterocycle inhibitor of fatty acid amide hydrolase.
Mileni M; Garfunkle J; Ezzili C; Cravatt BF; Stevens RC; Boger DL
J Am Chem Soc; 2011 Mar; 133(11):4092-100. PubMed ID: 21355555
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders.
Ahn K; Johnson DS; Cravatt BF
Expert Opin Drug Discov; 2009 Jul; 4(7):763-784. PubMed ID: 20544003
[TBL] [Abstract][Full Text] [Related]
9. X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase.
Mileni M; Garfunkle J; Ezzili C; Kimball FS; Cravatt BF; Stevens RC; Boger DL
J Med Chem; 2010 Jan; 53(1):230-40. PubMed ID: 19924997
[TBL] [Abstract][Full Text] [Related]
10. The endocannabinoid system and pain.
Guindon J; Hohmann AG
CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):403-21. PubMed ID: 19839937
[TBL] [Abstract][Full Text] [Related]
11. The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1.
Fowler CJ; Naidu PS; Lichtman A; Onnis V
Br J Pharmacol; 2009 Feb; 156(3):412-9. PubMed ID: 19226258
[TBL] [Abstract][Full Text] [Related]
12. A copper-catalyzed, pH-neutral construction of high-enantiopurity peptidyl ketones from peptidic s-acylthiosalicylamides in air at room temperature.
Liebeskind LS; Yang H; Li H
Angew Chem Int Ed Engl; 2009; 48(8):1417-21. PubMed ID: 19145620
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of high enantiopurity N-protected alpha-amino ketones by thiol ester-organostannane cross-coupling using pH-neutral conditions.
Li H; Yang H; Liebeskind LS
Org Lett; 2008 Oct; 10(19):4375-8. PubMed ID: 18759432
[TBL] [Abstract][Full Text] [Related]
14. Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH).
Timmons A; Seierstad M; Apodaca R; Epperson M; Pippel D; Brown S; Chang L; Scott B; Webb M; Chaplan SR; Breitenbucher JG
Bioorg Med Chem Lett; 2008 Mar; 18(6):2109-13. PubMed ID: 18289847
[TBL] [Abstract][Full Text] [Related]
15. Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields.
Myllymäki MJ; Käsnänen H; Kataja AO; Lahtela-Kakkonen M; Saario SM; Poso A; Koskinen AM
Eur J Med Chem; 2009 Oct; 44(10):4179-91. PubMed ID: 19539407
[TBL] [Abstract][Full Text] [Related]
16. Structure based design of novel irreversible FAAH inhibitors.
Wang JL; Bowen SJ; Schweitzer BA; Madsen HM; McDonald J; Pelc MJ; Tenbrink RE; Beidler D; Thorarensen A
Bioorg Med Chem Lett; 2009 Oct; 19(20):5970-4. PubMed ID: 19765986
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of polar head group containing 2-keto-oxazole inhibitors of FAAH.
Rusch M; Zahov S; Vetter IR; Lehr M; Hedberg C
Bioorg Med Chem; 2012 Jan; 20(2):1100-12. PubMed ID: 22196515
[TBL] [Abstract][Full Text] [Related]
18. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
Seierstad M; Breitenbucher JG
J Med Chem; 2008 Dec; 51(23):7327-43. PubMed ID: 18983142
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
